Articles

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain;
Levine Cancer Institute/Atrium Health, Charlotte, NC, USA;
University Hospital of Salamanca/IBSAL, Salamanca, Spain;
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam, The Netherlands;
Winship Cancer Institute, Emory University, Atlanta, GA, USA;
University Hospital of Nantes, Nantes, France;
Institut Català d'Oncologia, HGTiP, Barcelona, Spain;
Vejle Hospital and University of Southern Denmark, Vejle, Denmark;
Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau,Tours, France;
Janssen Research and Development, LLC, Raritan, NJ, USA;
Janssen Research and Development, Beerse, Belgium;
Janssen Research and Development, LLC, Spring House, PA, USA;
Janssen Research and Development, LLC, Spring House, PA, USA;
Janssen Research and Development, LLC, Spring House, PA, USA;
Janssen Research and Development, LLC, High Wycombe, United Kingdom;
Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden;
Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA
Haematologica Early view Apr 30, 2020 https://doi.org/10.3324/haematol.2019.243790